Table 4.
The demographic profile and hematological parameters of patients with and without malignancy.
| HE with malignancy N=30 |
HE without malignancy N=54 |
p value | |
|---|---|---|---|
| Median (Range) | |||
| Age (years) | 40 (1–68) | 30 (1–71) | 0.251 |
| Duration of HE (months) | 1 (0.5–45) | 2 (0.25–48) | 0.99 |
| Hemoglobin (g/L) | 102 (34–182) | 116 (62–181) | 0.013* |
| Max TLC x109/L | 41.4 (13.7–407.3) | 28.2(6.6–151.4) | 0.035* |
| Eosinophil% | 34 (8–84) | 65 (14–92) | 0.0004* |
| Max AEC (x109/L) | 14.3 (3.1–135) | 19.3 (1.9–128.7) | 0.32 |
| Platelet x109/L | 179 (12–517) | 286 (26–614) | 0.00162* |
| Peripheral blood blast% | 0 (0–84) | 0 (0–0) | 0.008* |
| Bone marrow blast% | 4 (0–84) | 2 (0–5) | 0.005* |
| Bone marrow Eo% | 22 (7–59) | 29 (4–79) | 0.06 |
| No. of patients with bone marrow fibrosis | 7 | 2 | 0.02* |
| IgE levels (IU/ml) | 493 (5–10000) | 2141 (50–10000) | -nt |
| No. of patients with organomegaly (hepatomegaly and/or splenomegaly) | 15 | 14 | 0.04* |
AEC - absolute eosinophil count, TLC- total leukocyte count, Eo – eosinophil, nt – not tested due to lack of sufficient number of patients in one of the groups.
*
statistically significant.